Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences updates investor presentation; first US Phase 3 acne patient dosed

Neutral Impact 2 of 5 other Written later

Sagimet Biosciences filed an updated investor presentation on October 22, 2026, furnished under Regulation FD rather than filed. The deck reports that the first patient was dosed in the AURORA Phase 3 acne trial in the US in October 2026, and it cites $257.6 million in cash as of June 30, 2026, which the company expects to fund operations through mid-2029.

Key points

  • Updated investor presentation dated October 22, 2026, attached as Exhibit 99.1 and furnished under Item 7.01
  • First patient dosed in the AURORA Phase 3 acne trial in the US in October 2026; topline results expected in 2H 2027
  • $257.6 million cash, cash equivalents and marketable securities as of June 30, 2026 (unaudited), plus a $115 million underwritten offering completed in September 2026

The filing

CompanySagimet Biosciences Inc. (SGMT)
Form8-K, current report
Filed with the SECOct 22, 2026, 7:15 AM ET
Accession number0001193125-26-428314

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.